Smesny S - Search Results

1

Phospholipase A₂ activity in first episode schizophrenia: associations with symptom severity and outcome at week 12.

Smesny S, Kunstmann C, Kunstmann S, Willhardt I, Lasch J, Yotter RA, Proffitt TM, Kerr M, Marculev C, Milleit B, Milleit C, Nenadic I, Amminger P, McGorry PD, Sauer H, Berger GE. Smesny S, et al. World J Biol Psychiatry. 2011 Dec;12(8):598-607. doi: 10.3109/15622975.2010.541283. Epub 2010 Dec 14. World J Biol Psychiatry. 2011. PMID: 21143005

2

Do neuroleptics alter the cerebral intracellular pH value in schizophrenics?-a (31)P-MRS study on three different patient groups.

Riehemann S, Hübner G, Smesny S, Volz HP, Sauer H. Riehemann S, et al. Among authors: smesny s. Psychiatry Res. 2002 Jun 15;114(2):113-7. doi: 10.1016/s0925-4927(02)00007-0. Psychiatry Res. 2002. PMID: 12036511

3

Potential use of the topical niacin skin test in early psychosis -- a combined approach using optical reflection spectroscopy and a descriptive rating scale.

Smesny S, Berger G, Rosburg T, Riemann S, Riehemann S, McGorry P, Sauer H. Smesny S, et al. J Psychiatr Res. 2003 May-Jun;37(3):237-47. doi: 10.1016/s0022-3956(03)00006-2. J Psychiatr Res. 2003. PMID: 12650743

4

Fluorometric assays of phospholipase A2 activity with three different substrates in biological samples of patients with schizophrenia.

Lasch J, Willhardt I, Kinder D, Sauer H, Smesny S. Lasch J, et al. Among authors: smesny s. Clin Chem Lab Med. 2003 Jul;41(7):908-14. doi: 10.1515/CCLM.2003.138. Clin Chem Lab Med. 2003. PMID: 12940517

5

Effects of lorazepam on the neuromagnetic mismatch negativity (MMNm) and auditory evoked field component N100m.

Rosburg T, Marinou V, Haueisen J, Smesny S, Sauer H. Rosburg T, et al. Among authors: smesny s. Neuropsychopharmacology. 2004 Sep;29(9):1723-33. doi: 10.1038/sj.npp.1300477. Neuropsychopharmacology. 2004. PMID: 15127083 Clinical Trial.

6

The influence of age and gender on niacin skin test results - implications for the use as a biochemical marker in schizophrenia.

Smesny S, Rosburg T, Klemm S, Riemann S, Baur K, Rudolph N, Grunwald S, Sauer H. Smesny S, et al. J Psychiatr Res. 2004 Sep-Oct;38(5):537-43. doi: 10.1016/j.jpsychires.2004.01.007. J Psychiatr Res. 2004. PMID: 15380405 Clinical Trial.

7

Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia.

Smesny S, Kinder D, Willhardt I, Rosburg T, Lasch J, Berger G, Sauer H. Smesny S, et al. Biol Psychiatry. 2005 Feb 15;57(4):399-405. doi: 10.1016/j.biopsych.2004.11.018. Biol Psychiatry. 2005. PMID: 15705356

8

Bioactive lipids in schizophrenia.

Berger GE, Smesny S, Amminger GP. Berger GE, et al. Among authors: smesny s. Int Rev Psychiatry. 2006 Apr;18(2):85-98. doi: 10.1080/09540260600583072. Int Rev Psychiatry. 2006. PMID: 16777663 Review.

9

Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia.

Smesny S, Rosburg T, Nenadic I, Fenk KP, Kunstmann S, Rzanny R, Volz HP, Sauer H. Smesny S, et al. Neuroimage. 2007 Apr 1;35(2):729-37. doi: 10.1016/j.neuroimage.2006.12.023. Epub 2006 Dec 29. Neuroimage. 2007. PMID: 17276699

10

Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia.

Smesny S, Rosburg T, Baur K, Rudolph N, Sauer H. Smesny S, et al. Neuropsychopharmacology. 2007 Oct;32(10):2067-73. doi: 10.1038/sj.npp.1301343. Epub 2007 Feb 21. Neuropsychopharmacology. 2007. PMID: 17314920

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

109 results

Search Page

Filters